retatrutide nafld nonalcoholic fatty liver disease nash trial Retatrutide, the triple G, Glucagon-GIP-GLP-1 based triagonist produces substantial resolution of liver fat #NAFLD in PPL with #obesity #ADA2023 @ADA_DiabetesPro @AmDiabetesAssn #NASH trial coming Retatrutide Doesn’t ONLY Help With

Holick, New England Journal of Medicine , 2007)

-Angelica lactone exerts strong chemoprotective effects by selective enhancement of glutathione-S-thansferase (GST) and UDP-glucononosyltransferase (UGT) detoxification enzymes

GIP receptor activation improves how the body processes and stores fat, enhances insulin sensitivity beyond what GLP-1 alone achieves, and appears to reduce the inflammatory signaling associated with excess adipose tissue

Patients had higher odds of achieving 10% or greater weight reduction after one year of treatment if they: In addition to looking at the factors that affect a persons weight trajectory, researchers tracked glycemic control in patients who had pre-diabetes at the start of the study

Customized Peptide Protocol : BPC-157 is delivered via oral capsules or subcutaneous injection, often paired with adjunctive peptides

works very well